In the US, Canakinumab (canakinumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome and Muckle Wells Syndrome.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Immunoglobulin G1, anti-[Homo sapiensinterleukin 1, beta (IL1B)] human monoclonal ACZ885; gamma1 heavy chain (Homo sapiensVH-IGHG1*03) (221-214)-disulfide with kappa light chain (Homo sapiensV-KAPPA-IGKC*01); (227-227:230-230 (WHO )
- Canakinumabum (Latin)
- Canakinumab (German)
- Canakinumab (French)
- Canakinumab (Spanish)
- Canakinumab (OS: USAN, BAN)
- ACZ885 (IS)
- UNII-37CQ2C7X93 (IS)
Novartis, Canada; Novartis, Switzerland; Novartis, Germany; Novartis, France; Novartis, United Kingdom; Novartis, Lithuania; Novartis, Norway; Novartis, Sweden; Novartis, United States; Novartis Europharm, Austria; Novartis Europharm Limited, Latvia; Novartis Farma, Italy; Novartis Farmaceutica, Spain; Novartis Healthcare, Philippines
|BAN||British Approved Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.